期刊
EMERGING INFECTIOUS DISEASES
卷 21, 期 11, 页码 1966-1972出版社
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2111.150267
关键词
-
资金
- Japan Society for Promotion of Science [26461569]
- Morinaga Foundation for Health Nutrition [AN601269]
- Grants-in-Aid for Scientific Research [26461569] Funding Source: KAKEN
Human parechovirus type 3 (HPeV3) is an emerging pathogen that causes sepsis and meningoencephalitis in young infants. To test the hypothesis that maternal antibodies can protect this population, we measured neutralizing antibody titers (NATs) to HPeV3 and other genotypes (HPeV1 and HPeV6) in 175 cord blood samples in Japan. The seropositivity rate (>= 1:32) for HPeV3 was 61%, similar to that for the other genotypes, but decreased significantly as maternal age increased (p<0.001). Furthermore, during the 2014 HPeV3 epidemic, prospective measurement of NATs to HPeV3 in 45 patients with severe diseases caused by HPeV3 infection showed low NATs (<= 1:16) at onset and persistently high NATs (>= 1:512) until age 6 months. All intravenous immunoglobulin samples tested elicited high NATs to HPeV3. Our findings indicate that maternal antibodies to HPeV3 may help protect young infants from severe diseases related to HPeV3 and that antibody supplementation may benefit these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据